Zeiss won FDA approval for its ReLEx SMILE product for performing myopia treatment on patients with astigmatism. The product is offered on the company’s VisuMax femtosecond laser system, allowing the creation of a lenticule inside the cornea and access incision in one step. The laser is used to create millions of “photodisruptions” within the targeted tissue, gently cutting through it with high precision.
A major benefit of ReLEx SMILE is that it allows for significantly smaller flaps to be created compared to LASIK, potentially resulting in 80% smaller side-cuts and 30% smaller cap cuts.
“Thanks to our continued collaboration with partner surgeons worldwide, we are able to pave the way for new developments and technologies in the refractive space,” said Dr. Ludwin Monz, President, and CEO of Carl Zeiss Meditec, in a statement. “Now with the FDA approval for US SMILE® Astigmatism, we can now extend this great treatment option to US Astigmatism patients as well.”
Product page: ZEISS ReLEx SMILE…
Via: ZEISS…